
Work Here?
Arthrex is a private medical device company that specializes in arthroscopy and sports medicine. It develops and distributes tools, implants, and technologies used in minimally invasive joint surgery, with a focus on educating surgeons and expanding surgical techniques. The company’s products enable doctors to perform arthroscopic procedures through small incisions, using specialized instruments and implants designed for precision and repair inside joints. Unlike many competitors, Arthrex remains privately held to reinvest in research and development, pursue long-term innovation, and avoid quarterly profit pressures. Its goal is to help surgeons treat their patients better by advancing orthopedic care through continuous education and a broad catalog of surgical solutions used globally.
Industries
Industrial & Manufacturing
Healthcare
Company Size
5,001-10,000
Company Stage
Early VC
Total Funding
$2.2M
Headquarters
Naples, Florida
Founded
1981
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$2.2M
Above
Industry Average
Funded Over
1 Rounds
Arthrex TightRope SB: product release and device features Reported. 03/02/2026 Arthrex has announced the release of the TightRope SB; in a PRNewswire press release, the company describes it as the first device on the market for anterior cruciate ligament (ACL) reconstruction using all-suture, soft-button technology. The company presents the device as an all-suture option for ACL fixation and outlines the concept in terms of intended use, construction, and intraoperative handling. The announcement also includes clinician and company remarks and references early-experience signals cited in the release. On availability, the announcement states that the device has been released commercially and positions it for ACL reconstruction, while also describing applicability to ACL repair in addition to reconstruction. It reports that nearly two thousand implants have been used to date in procedures across the U.S. The release also states that the implant is offered in configurations intended to support ACL reconstruction using all graft types and includes use "for ACL primary repair procedures" within the described procedural scope. Taken together, the positioning is described as spanning ACL reconstruction fixation and primary repair use cases. On design and intraoperative attributes, the release describes the device as an all-suture soft-button implant that uses a flat-tape loop intended to hold the reconstructed ligament in place. It also notes that the implant is radiopaque, which the announcement says is intended to help surgeons confirm position during and after surgery, and it describes availability in multiple configurations. A quoted surgeon, Rachel M. Frank, MD, characterizes the system as a "metal-free, screw-free option" and describes an adjustable all-suture construct that, in her remarks, allows intraoperative flexibility in graft tensioning along with a low-profile footprint; the quote also notes that evaluation is underway to assess clinical outcomes. Arthrex also states that the implant's radiopacity supports confirmation of position during and after surgery, and the quoted surgeon reiterates intraoperative flexibility in graft tensioning with the adjustable, all-suture construct. The announcement highlights early adoption and rollout signals through a brief account of initial cases, stating that Dr. Frank completed the first cases with the device in June 2025 and describing them as QuadLink all-inside ACL reconstructions performed with the InternalBrace technique. Beyond those early cases, the release frames the product as an evolution of Arthrex ACL technology and reiterates the metal-free construct concept in company commentary rather than presenting clinical performance data. It also notes third-party recognition, stating that the device received a gold Edison Award in April 2025 in a healthcare-related category. In aggregate, the messaging emphasizes that the implant is released, has been used in early cases, and has been publicly recognized as part of the launch narrative. Key Takeaways: * The announcement reports Arthrex's commercial release of TightRope SB and describes it as an all-suture soft-button implant intended for ACL reconstruction, with additional framing that includes ACL repair/primary repair use in the described scope. * Reported device attributes include a flat-tape loop, radiopacity for position confirmation during and after surgery, and multiple configurations; quoted remarks also describe adjustability and a metal-free construct. * The release cites early-use signals (nearly two thousand U.S. uses) and notes recognition via an Edison Award, presented as part of the product launch context.
Arthrex has released the TightRope SB All-Suture Implant for ACL reconstruction, offering a metal-free, screw-free fixation solution. The device uses soft-button technology with a flat-tape loop to secure grafts during ACL reconstruction and repair procedures. The implant eliminates rigid materials whilst maintaining adjustable fixation, supporting improved knee stability and range of motion. It features radiopaque properties for surgical positioning verification and is available in multiple configurations for different graft types. Dr Rachel M Frank from CU Anschutz Orthopedics completed the first cases in June 2025. The device received gold at the 38th annual Edison Awards in April 2025 in the Healthcare Environment and Patient Care Solutions category. ACL reconstruction is amongst the most performed orthopaedic procedures worldwide, serving patients from elite athletes to active adults.
Florida Cancer Specialists Foundation receives grant from Arthrex Charitable Giving Program. Bradenton, Fla., February 18, 2026 - Florida Cancer Specialists Foundation is pleased to announce it has received a grant from the Arthrex Charitable Giving Program to support its Compassionate Care for Cancer Patients in Need Program. Arthrex is a global medical device company and leader in multispecialty minimally invasive surgical technology innovation, scientific research, manufacturing quality and medical education. With a corporate mission of Helping Surgeons Their Patients Better(R), Arthrex has pioneered the field of arthroscopy and sports medicine. "Support like this plays a vital role in ensuring the Foundation can continue to grow and meet the evolving financial needs of cancer patients who are undergoing treatment," said Lynn Rasys, Executive Director of Florida Cancer Specialists Foundation. "Sustaining our mission depends on meaningful support from organizations that believe in the importance of compassionate care, and we are grateful to the Arthrex Charitable Giving Program and the funds behind this grant." About Florida Cancer Specialists Foundation The Florida Cancer Specialists Foundation provides financial support to qualified adult cancer patients in the state of Florida for non-medical living expenses, such as rent or mortgage payments, car payments, and utility bills. By easing the financial burden of everyday expenses, the Foundation helps patients focus on what matters most - their treatment and recovery. Thanks to the generosity of Florida Cancer Specialists & Research Institute physicians, 100% of donations received go directly toward helping patients in need. The Foundation is a 501(c)(3) nonprofit organization located at 5985 Silver Falls Run, Suite 210, Bradenton, Florida 34211. Learn more at FCSF.org or call (941) 677-7181. About the Arthrex Charitable Giving Program The Arthrex Charitable Giving Program supports more than 100 501(c)(3) public charities in Florida, South Carolina, and California with annual donations for programs and services. Its areas of support include local community organizations focused on education, health, and wellness. Nonprofit organizations may apply for support each year between July 15 and September 15. Florida Cancer Specialists Foundation will notify applicants of its decision by the end of December. If approved, funding will be disbursed by December 31. Lynn Rasys, Executive Director Florida Cancer Specialists Foundation [email protected] (941) 677.7184
The Shelter for Abused Women & Children receives grant from Arthrex. The Shelter for Abused Women & Children is honored to receive a grant from Arthrex to support its mission of providing safety, healing, and hope for survivors of domestic violence and abuse. This generous gift will help fund essential needs, programs, and direct services, allowing Women & Children, Inc. to respond where the need is greatest. Women & Children, Inc. is deeply grateful to Arthrex for their partnership and commitment to strengthening its community and improving the lives of the women, children, and families Women & Children, Inc. serve.
NAPLES, Fla., Aug. 1, 2025 /PRNewswire/ - Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious honors for product innovation at the 38th annual Edison Awards.
Find jobs on Simplify and start your career today
Industries
Industrial & Manufacturing
Healthcare
Company Size
5,001-10,000
Company Stage
Early VC
Total Funding
$2.2M
Headquarters
Naples, Florida
Founded
1981
Find jobs on Simplify and start your career today